

FIT Cancer 13

13th FORUM ON Translational
Immunology and

**IMMUNOTHERAPY
OF CANCER**

13.º FORO DE Inmunología
Traslacional e

**INMUNOTERAPIA
DEL CÁNCER**

Madrid 11 • 12 March

2027

Hotel Crowne Plaza Madrid

Organizado por / Organized by



FIT Cancer 13

13th FORUM ON Translational Immunology and
IMMUNOTHERAPY OF CANCER

Call for Abstracts

FIT-Cancer 13

13th FORUM ON Translational Immunology and

IMMUNOTHERAPY OF CANCER

Madrid 11 ▪ 12 March, 2027

CONDITIONS OF PARTICIPATION

Submissions accepted for the 13th Forum on Translational Immunology and Immunotherapy of Cancer – FIT Cancer 13 – will be published in an Abstract Book format, preferentially in an indexed scientific journal to be determined (see previous **Abstract Books here**). The Scientific Committee reserves the right to decide if an abstract is not suitable for publication.

Abstracts must be written in English, and the submitting author is responsible for ensuring the accuracy of all information, including affiliations, language and abbreviations. GETICA may request editorial or technical corrections before publication. The corresponding author must review and return any requested corrections within the deadline communicated by the Technical Secretariat. Failure to provide a compliant final version may prevent inclusion in the Abstract Book.

Authors will not select a preferred presentation format when submitting. All abstracts will be evaluated and ranked by the Selection Committee. The three highest-scoring accepted abstracts will be assigned to oral presentation, and all other accepted abstracts will be assigned to poster presentation.

Works that have not been previously published or presented at other conferences will be given preference. Updated results from previously reported work may be submitted if the submitting author provides references to the previously published results. At submission, the author must explicitly declare any prior presentation, publication or closely related manuscript. The Scientific Committee may exclude an abstract from the meeting or Abstract Book if prior dissemination is incompatible with conference or journal editorial requirements.

Submitting a work for consideration at the conference implies the participant's complete and unconditional acceptance of these terms. It also authorizes GÉTICA to make minor copy-editing and formatting changes required for publication, without altering the scientific meaning.

Please submit all proposals exclusively via the following website:

<https://congresos.grupoaran.com/fitcancer13>

Proposals sent by any other means will not be considered.

Proposals must be submitted online no later than 11:59 pm (CET) on December 17, 2026

The Scientific Committee will award a prize for the best oral communication (€250) and the best poster (€100), selected by the Evaluation Committee composed of GÉTICA representatives and selected symposium participants. The prize announcement and award ceremony will take place during the closing session of FIT Cancer 13.



FIT Cancer 13

13.º FORO DE Inmunología Traslacional e
INMUNOTERAPIA DEL CÁNCER

Awardees will be asked to prepare a video of up to 3 minutes for dissemination through GÉTICA digital media.

By submitting, authors consent to the inclusion of authors' names, affiliations, biographical material and abstract on the symposium website and in print or electronic indexes and search databases. The submitting author confirms that all co-authors have approved the submission and the potential publication of the abstract and its figures or tables.

RULES OF THE CALL

Proposals presenting basic, translational, clinical, epidemiological and/or computational research in cancer immunology and/or cancer immunotherapy are welcome. Proposals may also include relevant clinical experiences with immunotherapies in patients with cancer.

The three highest-scoring accepted abstracts will be selected for oral presentation. The remaining accepted abstracts will be presented as posters. The presentation format will be determined exclusively by the evaluation and ranking established by the Selection Committee; authors may not choose or request a modality.

Priority will be given to work focused on the following thematic areas:

- Cell therapies.
- New immunotherapy strategies for cancer treatment.
- Biomarkers of response or toxicity to immunotherapy.
- Integration of immunotherapies into multimodal treatments.
- Mechanisms of response or resistance to immunotherap

Presentation of a work requires the physical presence of the presenting author, who must be duly registered.

If the first author cannot attend, presentation may be delegated to a co-author, provided the Technical Secretariat is notified in advance and the co-author is registered and attends in person.

First authors who submit abstracts will be eligible to apply for a limited number of FIT Cancer 13 registration grants. Submission does not guarantee a grant. Applicants must indicate their interest at submission. Early registration is recommended to secure reduced fees irrespective of the grant decision.

An author may present more than one proposal.

RULES FOR PREPARING AND SUBMITTING PROPOSALS

Abstracts must be written in English and submitted in PDF or Word format, with the following structure:

- **Title:** no longer than 25 words. Use sentence case and avoid unnecessary abbreviations.
- **Authors:** provide first and last names. The first author should be the presenting author. Enter each name and affiliation exactly as they should appear in the publication.
- **Affiliation of the first author:** select the workplace from the options in the system. If it is not listed, use "Other work center" and complete all requested information.

FIT Cancer 13

13th FORUM ON Translational Immunology and
IMMUNOTHERAPY OF CANCER

- **Abstract:** maximum 350 words, with the sections Introduction and Objectives, Materials and Methods, Results, and Conclusions. Do not include references in the abstract body. Define non-standard abbreviations at first use and use them consistently.
- **Funding:** indicate grants and other funding sources in the final line. If none, state "Funding: None". Include any applicable conflict-of-interest declaration in the field provided by the submission platform.
- **Figures and tables:** a maximum of three items in total may be included. Each item must be cited in the abstract and have a concise legend. Figures must be uploaded separately as high-quality JPG or PNG files at a minimum resolution of 300 dpi and a minimum width of 1,200 pixels. Do not submit screenshots. Graphs must be exported directly from the original software. All labels, axes, symbols and numbers must be legible, in English, and preferably use Arial or Helvetica at a size equivalent to at least 8 pt in the final figure. Use a decimal point rather than a decimal comma. Multipanel figures must be combined into one final file and labeled A, B, C, etc.; titles, legends and panel labels must not be added as floating text boxes. Tables must remain editable in the Word document and must not be submitted as images.
- Images must not contain institutional logos, decorative borders or patient-identifying information. Authors are responsible for obtaining any permissions required for material reproduced or adapted from another source.
- Do not include personal or identifying data relating to patients or their relatives.

As a final submission step, attach an additional anonymized version in Word format that does not include author names, affiliations, institutions, acknowledgements or other information that could identify the research group. Insert the figures and editable tables in their corresponding position in this anonymized document. Separately upload the original figure files in accordance with the technical requirements above.

If submitting more than one work as first author, use the same username, password and email address for every proposal.

After acceptance, the corresponding author may be asked to provide a final non-anonymized Word version and the original figure files. The scientific content may not be substantively changed after acceptance without written authorization from the Scientific Committee.

SELECTION PROCESS

- All proposals will be evaluated by the Selection Committee. Results will be communicated on January 19, 2027. The decision will indicate acceptance or rejection, presentation format, and the expected date and time of presentation.
- The three accepted abstracts with the highest final scores will be classified as oral presentations. All other accepted abstracts will be classified as poster presentations. Authors will not select the presentation format. In the event of a tie affecting the third oral presentation, the higher score for scientific quality and methodological robustness will prevail, followed, if necessary, by originality and innovation. The Selection Committee will resolve any remaining tie.
- Inclusion in the Abstract Book will depend on the Scientific Committee's criteria and on compliance with the technical and editorial requirements set out in these bases.
- The Technical Secretariat will notify the submitting author of the evaluation result and, for accepted works, the date, time and room of the presentation.

FIT Cancer 13

13.º FORO DE Inmunología Traslacional e
INMUNOTERAPIA DEL CÁNCER

EVALUATION CRITERIA

- All submitted proposals will be peer-reviewed by the Selection Committee designated by GÉTICA. Each abstract will be assessed independently by at least two reviewers using a standardized scoring form. Reviewers must declare any conflict of interest and will not evaluate abstracts for which a conflict exists. Where scores are materially discrepant, the Selection Committee may assign an additional review.
- Abstracts will be assessed according to:
 - **Scientific quality** and robustness of methodology.
 - **Originality and innovation.**
 - **Relevance** to cancer immunology and/or cancer immunotherapy.
 - **Clarity** of objectives, results and conclusions.
 - **Potential impact on research,** clinical practice or patient care.
- The ranking will be based on the final evaluation score. The Selection Committee may reject abstracts that do not reach the minimum scientific or formal quality required, irrespective of ranking.

All accepted posters will be displayed, and their authors must be present during the official poster session to defend their work and answer questions. A limited number of posters, selected according to abstract score, will be formally evaluated for the Best Poster award.

- Best Oral Presentation and Best Poster will be awarded based on the Evaluation Committee's assessment of the work presented in person, considering scientific quality and quality of delivery.
- The decisions of the Evaluation Committee will be final.

RULES FOR PRESENTING AN ACCEPTED WORK

Oral presentations

- The three highest-scoring accepted abstracts will be presented orally. Each presentation will have a strict limit of 5 minutes followed by 2 minutes for discussion. Presentations must be emailed or delivered on a USB drive to the Technical Secretariat at least 24 hours before the session begins.
- Slides must be prepared in English, and the oral presentation must be delivered in English.

Posters

- Posters must have a maximum size of 120 cm high by 90 cm wide and will be displayed in the designated poster area during the congress.
- Authors must be present during the official poster session. Posters shortlisted for formal evaluation will be selected according to abstract score.
- The first author or designated presenting author of each shortlisted poster must attend the official evaluation session to discuss the work and answer questions.